Effective adoptive transfer of haploidentical tumor-specific t cells in B16-melanoma bearing mice

Chinese Medical Journal

Volumn 125, Issue 5, 2012, Pages 794-800

  Cui, Nai Peng ^a   Xie, Shao Jian ^a   Han, Jin Sheng ^a   Ma, Zhen Feng ^b   Chen, Bao Ping ^b   Cai, Jian Hui ^a,c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

^c HEBEI GENERAL HOSPITAL   (China)

Author keywords

Adoptive immunotherapy; Adoptive transfer; B16 melanoma; Graft versus host disease; Tumor microenvironment

Indexed keywords

INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDENTICAL T LYMPHOCYTE; HISTOLOGY; ISOGRAFT; LEUKOCYTE COUNT; MALE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR REGRESSION; WHOLE BODY RADIATION;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84863377918     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.05.013     Document Type: Article

References (29)

1. Ngo MC, Rooney CM, Howard JM, Heslop HE. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet 2011; 20: R93-99.
2. van der Vliet HJ, Balk SP, Exley MA. Natural killer T cell-based cancer immunotherapy. Clin Cancer Res 2006; 12: 5921-5923.
3. van Herpen CM, De Mulder PH. Locoregional immunotherapy in cancer patients: review of clinical studies. Ann Oncol 2000; 11: 1229-1239.
4. Huang XJ. HLA-mismatched/haploidentical hematopoietic stem cell transplantation: a field in which Chinese doctors are making great contributions. Chin Med J 2010; 123: 1235-1240.
5. Kroger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361-3363.
6. Ocadlikova D, Zahradova L, Kovarova L, Penka M, Zaloudik J, Buchler T, et al. Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy. Med Oncol 2006; 23: 377-384.
7. Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008; 112: 4746-4754.
8. Wynn RF, Arkwright PD, Haque T, Gharib MI, Wilkie G, Morton-Jones M, et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol 2005; 6: 344-346.
9. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A, et al. Treatment of Epstein-Barr-virus-positive post-transplan-tation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-442.
10. Gattinoni L, Powell DJ, Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
11. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28: 258-267.
12. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175: 7046-7052.
13. Igietseme JU, Smith K, Simmons A, Rayford PL. Effect of gamma-irradiation on the effector function of T lymphocytes in microbial control. Int J Radiat Biol 1995; 67: 557-564.
14. Li SZ, Zheng XB, Peng F, Ye YB, Chen Q. Irradiated haploidentical donor leukocyte infusions as an adoptive immunotherapy strategy to induce host-versus-tumor effects. Tumori 2011; 97: 522-531.
15. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
16. Xie Y, Wu M, Song R, Ma J, Shi Y, Qin W, et al. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 781-791.
17. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, et al. Immunotherapy of distant metastatic disease. Ann Oncol 2009; 20: vi41-vi50.
18. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907-912.
19. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
20. Haas J, Hug A, Viehover A, Fritzsching B, Falk CS, Filser A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35: 3343-3352.
21. Feng LL, Wang X. Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy. Chin Med J 2010; 123: 3334-3342.
22. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
23. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005; 102: 5126-5131.
24. Chen H, Qin J, Wei P, Zhang J, Li Q, Fu L, et al. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukot Essent Fatty Acids 2009; 80: 195-200.
25. Tsuji-Takayama K, Suzuki M, Yamamoto M, Harashima A, Okochi A, Otani T, et al. The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol 2008; 181: 3897-3905.
26. Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. Exp Hematol 2000; 28: 1225-1231.
27. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
28. Ribas A. Update on immunotherapy for melanoma. J Natl Compr Canc Netw 2006; 4: 687-694.
29. Ma JX, Xia JB, Cheng XM, Wang CZ. 1,25-Dihydroxyvitamin D3 pretreatment enhances the efficacy of allergen immunotherapy in a mouse allergic asthma model. Chin Med J 2011; 123: 3591-3596.